

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

SNU-216

RRID:CVCL_3946

Type: Cell Line

Proper Citation

RRID:CVCL_3946

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3946

Proper Citation: RRID:CVCL_3946

Description: Cell line SNU-216 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Gastric tubular adenocarcinoma

Defining Citation: [PMID:9033653](#), [PMID:15723654](#), [PMID:19956504](#), [PMID:22460905](#), [PMID:24807215](#), [PMID:25343454](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:29435981](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Korean., Part of: Seoul National University (SNU) cell line collection., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SNU-216

Synonyms: SNU216, NCI-SNU-216

Cross References: BTO:BTO_0004988, EFO:EFO_0006754, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioSample:SAMN03473182, BioSample:SAMN10988071, cancercellines:CVCL_3946, Cell_Model_Passport:SIDM01393, CGH-DB:124-1, CGH-DB:9012-4, CLS:305630, Cosmic:685589, Cosmic:848139, Cosmic:1067205, Cosmic:1090453, Cosmic:1151969, Cosmic:1528874, Cosmic:2484970, DepMap:ACH-000466, EGA:EGAS00001000610, GEO:GSM887617, GEO:GSM888701, GEO:GSM1374887, IARC_TP53:7418,

KCLB:00216, LiGeA:CCL_434, PharmacDB:SNU216_1451_2019,
Progenetix:CVCL_3946, Wikidata:Q54955148

ID: CVCL_3946

Record Creation Time: 20220427T221551+0000

Record Last Update: 20260904T015708+0000

Ratings and Alerts

No rating or validation information has been found for SNU-216.

No alerts have been found for SNU-216.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. Molecular cancer therapeutics, 25(5), 814.

He J, et al. (2026) UBE2B Drives NF- κ B Signaling and Gastric Cancer Progression through BIRC2-Mediated K63-Linked Ubiquitination of TRAF1. Molecular cancer research : MCR, 24(6), 487.

Kim B, et al. (2024) Predictive biomarkers for metachronous gastric cancer development after endoscopic resection of early gastric cancer. Cancer medicine, 13(16), e70104.

Peng Y, et al. (2024) Helicobacter pylori CagA-mediated ether lipid biosynthesis promotes ferroptosis susceptibility in gastric cancer. Experimental & molecular medicine, 56(2), 441.

Chen S, et al. (2024) Anchoring of hyaluronan glycocalyx to CD44 reduces sensitivity of HER2-positive gastric cancer cells to trastuzumab. The FEBS journal.

Liang B, et al. (2024) Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer. Cancer letters, 587, 216702.

Park J, et al. (2023) Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer. Scientific reports, 13(1), 22648.

Hu X, et al. (2023) Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. Cancer communications (London, England), 43(8), 909.

Nargund AM, et al. (2022) Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. *Cancer research*, 82(14), 2538.

Sakai H, et al. (2021) Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer. *Clinical and translational medicine*, 11(6), e454.

Seo EH, et al. (2020) ONECUT2 upregulation is associated with CpG hypomethylation at promoter-proximal DNA in gastric cancer and triggers ACSL5. *International journal of cancer*, 146(12), 3354.